Are newborns candidates for gene therapy? Explore who qualifies, how it works, safety risks, and why early diagnosis and expert centers can transform outcomes for rare infant conditions.

MEDICAL FIRSTS: ZOLGENSMA IS A GAME CHANGER FOR INFANTS

CAN NEWBORNS BE CANDIDATES FOR GENE THERAPY?

Yes. Certain rare genetic disorders can be targeted right after birth with gene therapies. Growing trials and approvals are ushering in a new era of hope in pediatric care.

HOW DOES GENE THERAPY WORK IN INFANTS?

FIRST IN VIVO GENE EDITING MILESTONE

In vivo gene editing enables precise, direct changes in infants’ genomes. Early gains in urea cycle disorders like OTC and CPS1 open doors for more rare conditions.

WHAT IS SMA? SIGNS AND TREATMENT

2025 SURGE: 79 NEW GENE THERAPY TRIALS

SAFETY AND ETHICS: A PARENT’S GUIDE

DELIVERY METHODS: FROM VIRAL VECTORS TO NANOPARTICLES

SUCCESS STORIES: EARLY TREATMENT, LASTING IMPACT

LIV HOSPITAL’S VISION: ADVANCING GENE THERAPY FOR INFANTS

Stories

[{"selector":"#anim-aa4856a9-7c25-4d10-9662-da4622618ec6","keyframes":{"opacity":[0,1]},"delay":100,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-13ae1c71-3664-4cc4-bcdb-cba55cb82d6a","keyframes":{"transform":["translate3d(-118.35205%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":100,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-303215a4-61f7-4587-912c-fd688e85be6b","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-756f6b35-2c07-4209-9b39-c338d35aabfa","keyframes":{"transform":["translate3d(-123.52942%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bb68f61e-be4a-4a30-8cfa-a8c728ce2eca","keyframes":{"opacity":[0,1]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8e22e76b-d0de-477e-96a6-940ce2bd65f5","keyframes":{"opacity":[0,1]},"delay":300,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-09d688ea-f4f2-43e9-9cd2-2691c70de7e5","keyframes":{"opacity":[0,1]},"delay":300,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e215842d-4f37-4724-8a8a-1214ab73b709","keyframes":{"opacity":[0,1]},"delay":300,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f357496e-ebf4-4b18-a1a9-11f5ad1bda25","keyframes":{"opacity":[0,1]},"delay":300,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-64309bfd-91e6-409d-ac3d-a258c6a1efeb","keyframes":{"opacity":[0,1]},"delay":400,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ef3dd6b2-d5cf-423b-8da5-66f436e348b7","keyframes":{"opacity":[0,1]},"delay":400,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bfdaf6d9-9f99-4852-90af-214b114d05c4","keyframes":{"opacity":[0,1]},"delay":400,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-cbb9b03d-294a-40b3-89b5-8391f84a810d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7885beaf-be64-45f9-99d2-240fac2ae23e","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-dda269eb-e5d1-44bd-adff-24395c038506","keyframes":{"opacity":[0,1]},"delay":500,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-34fec7f7-0184-4108-a380-7088e0fc1bc1","keyframes":{"opacity":[0,1]},"delay":500,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-07dab0a1-382e-4d8f-a83c-c8e32ca4f081","keyframes":{"opacity":[0,1]},"delay":500,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-fced6699-0e5b-4d42-ab92-009da3781474","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-cb53b3d3-a8bf-4f62-86a9-fc3674432427","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] See More See More See More

Are newborns candidates for gene therapy? Explore who qualifies, how it works, safety risks, and why early diagnosis and expert centers can transform outcomes for rare infant conditions.

ARE NEWBORNS CANDIDATES FOR GENE THERAPY?

INFANT NEWS:

MEDICAL FIRSTS: ZOLGENSMA IS A GAME CHANGER FOR INFANTS

Zolgensma delivers one time gene therapy for infants with SMA, markedly improving motor function. FDA approved and given to over 4,000 patients worldwide, it is now a leading option for newly diagnosed infants.

CAN NEWBORNS BE CANDIDATES FOR GENE THERAPY?

HOW DOES GENE THERAPY WORK IN INFANTS?

Healthy genes are delivered to cells via viral vectors or lipid nanoparticles, correcting or compensating for faulty genes. By targeting root causes, benefits can be long lasting or even durable.

FIRST IN VIVO GENE EDITING MILESTONE

WHAT IS SMA? SIGNS AND TREATMENT

A mutation in the SMN1 gene causes motor neuron loss, leading to weakness, low tone, and feeding or breathing issues. Zolgensma provides a functional SMN1 gene in a single infusion, potentially halting or reversing decline.

2025 SURGE: 79 NEW GENE THERAPY TRIALS

In Q1 2025, 79 new clinical trials launched. Across North America, Europe, and Asia Pacific, many focus on non cancer rare diseases driving rapid progress in infant impacting conditions.

SAFETY AND ETHICS: A PARENT’S GUIDE

Benefits are significant, risks are real: off target effects and long term outcomes require close monitoring. Families need transparent, unbiased guidance plus regular follow ups, genetic surveillance, and developmental assessments.

DELIVERY METHODS: FROM VIRAL VECTORS TO NANOPARTICLES

Delivery is personalized by disease and age. Vectors like AAV efficiently target specific cells, while lipid nanoparticles show promise for safely carrying genetic payloads.

SUCCESS STORIES: EARLY TREATMENT, LASTING IMPACT

Infants treated with Zolgensma show marked gains in motor milestones. CRISPR based approaches are yielding encouraging outcomes in disorders like CPS1 and OTC.

LIV HOSPITAL’S VISION: ADVANCING GENE THERAPY FOR INFANTS

With personalized protocols, advanced vector design, and continuous quality improvement, we deliver the latest, safest, and most effective therapies for infants. Contact Liv Hospital for appointments and details.

Stories

More

RARE CHILDHOOD DISEASES: ARE CANCERS UNCOMMON?

CAN AN OPHTHALMOLOGIST DETECT A BRAIN TUMOR? 6 CRITICAL EYE SIGNS

COMMONLY MISTAKEN FOR OVARIAN CANCER